Exome Asset Management LLC

NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$153.0M2026 Q3
Positions55
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.48.2%

Exome Asset Management LLC reported 55 positions worth $153.0M as of September 30, 2026 (13F filed November 16, 2026). Largest holding: GH (7.9%). Biggest move: reduce TXG ($6.6M).

10 / 55 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 GHGuardant Health$12.0M7.87%67,500——-19.2%
▸ 2 TGTXTG Therapeutics$10.5M6.84%187,671——+15.7%
▸ 3 ABVXAbivax S.A.$9.0M5.88%90,919———
▸ 4 PRAXPraxis Precision Medicines$8.6M5.65%29,681——+6.5%
▸ 5 COGTCogent Biosciences$6.7M4.41%210,523——-10.8%
▸ 6 LLYEli Lilly$6.4M4.15%5,492——+23.7%
▸ 7 NTRANatera$5.7M3.73%13,800——-30.2%
▸ 8 VERAVera Therapeutics$5.2M3.37%159,556——-13.0%
▸ 9 VKTXViking Therapeutics$4.8M3.14%147,497——-17.6%
▸ 10 IONSIonis Pharmaceuticals$4.8M3.12%107,034——-37.3%

Pro Feature

The remaining 45 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Exome Asset Management LLC hold as of Q3 2026?

Exome Asset Management LLC reported 55 positions worth $153.0M in its Q3 2026 13F filing. Largest positions: GH (7.9%), TGTX (6.8%), ABVX (5.9%), PRAX (5.6%) and COGT (4.4%).

What did Exome Asset Management LLC buy in Q3 2026?

New positions: CMPS, CLDX, MRK, PVLA and RAPP (9 in all). Added to: ABVX, VKTX, NKTR, CAI and VERA (17 in all).

What did Exome Asset Management LLC sell in Q3 2026?

Reduced: TXG, QURE, GKOS, UNH and ADAGENE INC (9 in all). Sold out entirely: AGIO, CBIO, AZN, INSM and RLAY (6 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.